Harmony Biosciences Holdings, Inc.
HRMY Nasdaq
SEC CIK 1802665
Follow Harmony Biosciences
Weekly email: filings, results
Revenue, last quarter
$268.9M
+12.3% vs same quarter last year
Net income
$48.2M
−5.2% vs same quarter last year
EPS, diluted
$0.81
−6.9% vs same quarter last year
Operating cash flow
$76.7M
−29.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $868.5M | $158.7M |
| FY24 | $714.7M | $145.5M |
| FY23 | $582M | $128.9M |
| FY22 | $437.9M | $181.5M |
| FY21 | $305.4M | $34.6M |
| FY20 | $159.7M | −$36.9M |
| FY19 | $6M | −$152M |
| FY18 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 77.2% | 24% | 18.3% |
| FY24 | 78.1% | 26.7% | 20.4% |
| FY23 | 79.2% | 33% | 22.1% |
| FY22 | 80.9% | 27.4% | 41.4% |
| FY21 | 81.8% | 28.7% | 11.3% |
| FY20 | 82.6% | 10.6% | −23.1% |
| FY19 | 73.7% | −2433.8% | −2535.1% |
| FY18 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $347.9M |
| FY24 | $218.7M |
| FY23 | $219.1M |
| FY22 | $144.3M |
| FY21 | $98.3M |
| FY20 | −$3M |
| FY19 | −$75.6M |
| FY18 | - |
- Harmony Biosciences
- Healthcare median
Show the numbers
| Year | Harmony Biosciences | Healthcare median |
|---|---|---|
| FY25 | 18.3% | −30.6% |
| FY24 | 20.4% | −47% |
| FY23 | 22.1% | −58% |
| FY22 | 41.4% | −80.4% |
| FY21 | 11.3% | −71.8% |
| FY20 | −23.1% | −62.2% |
| FY19 | −2535.1% | −46.2% |
| FY18 | - | −49.6% |